Imatinib (Gleevec)
Tyrosine kinase inhibitor (KIT, BCR-ABL, PDGFR)
- Response rate
- Effective in non-D816V cases; ineffective in D816V+ SM
- Onset
- Weeks–months
- Route
- Oral 400mg daily
- Line
- 1st
- IgM effect
- N/A
Evidence summary
FDA-approved (2006) for ASM without D816V or unknown KIT status. Inhibits wild-type KIT and select non-codon 816 mutants (e.g., K509I, F522C). D816V causes conformational resistance. Effective in well-differentiated SM (WDSM), which typically lacks D816V. Long-term remissions reported in non-D816V patients.